# COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

> **NCT05028374** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 119 (actual)

## Conditions studied

- Multiple Myeloma
- AL Amyloidosis
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** A single "booster" dose of the Moderna mRNA COVID-19 vaccine

## Key facts

- **NCT ID:** NCT05028374
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-17
- **Primary completion:** 2021-11-02
- **Final completion:** 2021-11-02
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028374, "COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05028374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*